[1]颜 鹏,方志勇,向 华.奥沙利铂及重组人血管内皮抑素经肝动脉灌注联合TACE治疗原发性肝癌[J].介入放射学杂志,2013,(02):121-124.
 YAN Peng,FANG Zhi? yong,XIANG Hua..Transhepatic arterial infusion of oxaliplatin and recombinant human endostatin combined with TACE for primary hepatocellular carcinoma[J].journal interventional radiology,2013,(02):121-124.
点击复制

奥沙利铂及重组人血管内皮抑素经肝动脉灌注联合TACE治疗原发性肝癌()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2013年02期
页码:
121-124
栏目:
肿瘤介入
出版日期:
2013-02-25

文章信息/Info

Title:
Transhepatic arterial infusion of oxaliplatin and recombinant human endostatin combined with TACE for primary hepatocellular carcinoma
作者:
颜 鹏 方志勇 向 华
Author(s):
YAN Peng FANG Zhi?蛳 yong XIANG Hua.
Department of Interventional Vascular Surgery, Hunan Provincial People’s Hospital, Changsha, Hunan Province 410005, China
关键词:
【关键词】 原发性肝癌 奥沙利铂 重组人血管内皮抑素 经肝动脉灌注
文献标志码:
A
摘要:
【摘要】 目的 观察奥沙利铂及重组人血管内皮抑素联合经肝动脉灌注(TACE)治疗原发性肝癌的疗效及不良反应。方法 2010年6月至2012年6月43例原发性肝癌患者采用TACE术中经肝动脉灌注奥沙利铂及重组人血管内皮抑素治疗,并根据肿瘤血管丰富程度分组,术后观察患者不良反应,并定期行实验室指标及肝脏CT/MRI/DSA评价治疗效果及不良反应。结果 富血管肿瘤组治疗的总有效率显著高于乏血管肿瘤组患者(85.7%比33.3%,P < 0.05),临床随访数据表明多数富血管的患者通过联合药物灌注治疗有效,生存时间6个月以上者达57.1%(16/28),对于乏血管肿瘤患者的治疗中病情进展的仅为26.7%(4/15)。结论 TACE术中经肝动脉灌注奥沙利铂联合重组人血管内皮抑素治疗原发性肝癌安全有效。

参考文献/References:

[1] Burroughs A, Hochhauser D, Meyer T. Systemic treatment and livertransplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum[J]. Lancet Oncol, 2004, 5: 409 ?蛳 418.[2] 卫生部原发性肝癌诊疗规范(2011版).[3] 高 嵩, 朱 旭, 杨仁杰, 等. TACE 联合奥沙利铂、 氟尿嘧啶、 亚叶酸钙肝动脉化疗治疗中晚期原发性肝癌[J]. 介入放射学杂志2012, 21: 377 ?蛳 383. [4] Rathore R, Safran H, Soares G, et al. Phase I study of hepaticartierial infusion of oxaliplatin in advanced hepatocelluar cancer: a brown university oncology group study[J]. Am J Clin Oncol, 2010, 33: 43 ?蛳 46.[5] 刘朝阳, 王德昌, 赵 俊. 奥沙利铂抗肿瘤作用的研究[J]. 实用癌症杂志, 2000, 15: 151 ?蛳 153.[6] 向 华, 孙 林. 加用重组人血管内皮抑素的TACE治疗对肝癌组织VEGF和MVD的影响[J]. 临床肿瘤学杂志, 2012, 17: 744 ?蛳 748.

相似文献/References:

[1]高 嵩,朱旭,杨仁杰,等. TACE联合奥沙利铂、氟尿嘧啶、亚叶酸钙肝动脉化疗治疗中晚期原发性肝癌[J].介入放射学杂志,2012,(05):377.
 ,,et al. TACE combined with hepatic arterial infusion chemotherapy using oxaliplatin, 5fluorouracil and folinic acid for intermediate and advanced hepatocellular carcinomas[J].journal interventional radiology,2012,(02):377.
[2]储玉山,朱小庆,张玉宇,等.索拉非尼联合奥沙利铂对肝癌HepG2细胞的抑制作用[J].介入放射学杂志,2011,(10):810.
 CHU Yu-shan,ZHU Xiao-qing,ZHANG Yu-yu,et al. The inhibitory effect of sorafenib together with oxaliplatin on the growth of human hepatic carcinoma cell line HepG2 in vitro[J].journal interventional radiology,2011,(02):810.
[3]王少雷,李 森,魏 宏,等.奥沙利铂与吡喃阿霉素介入治疗原发性肝癌的比较研究[J].介入放射学杂志,2012,(09):738.
 WANG Shao- lei,LI Sen,WEI Hong,et al. Interventional chemoembolization therapy of primary hepatocellular carcinoma: a comparative study between oxaliplatin and therarubicin[J].journal interventional radiology,2012,(02):738.
[4]高 峰,张雪娜,陈茂振,等.原发性肝癌TACE术后预防性抗生素应用价值研究[J].介入放射学杂志,2013,(02):151.
 GAO Feng,ZHANG Xue? na,CHEN Mao? zhen,et al.Prophylactic use of antibiotics after interventional procedures for primary hepatocellular carcinoma: its clinical significance[J].journal interventional radiology,2013,(02):151.
[5]李金鹏,石丛丛,宋金龙,等.18F?蛳 FDG PET/CT显像在索拉非尼治疗肝细胞癌预后评估中的应用[J].介入放射学杂志,2013,(03):193.
 LI Jin? peng,SHI Cong? cong,SONG Jin? long,et al.The application of 18F?蛳 FDG PET/CT imaging in evaluating the prognosis of hepatocellular carcinoma treated with sorafenib[J].journal interventional radiology,2013,(02):193.
[6]施振静,虞希祥,郝伟远,等.C臂CT在肝癌TACE术中评估碘油沉积的应用价值[J].介入放射学杂志,2013,(04):301.
 SHI Zhen? jing,YU Xi? xiang,HAO Wei? yuan,et al.Clinical value of DynaCT scanning in assessing iodized oil deposition degree within the tumor during transcatheter arterial chemoembolization for hepatocellular carcinoma[J].journal interventional radiology,2013,(02):301.
[7]徐国斌,易广新,熊斌,等.原发性肝癌术后早期肝内复发转移36例的介入治疗[J].介入放射学杂志,2013,(04):325.
 XU Guo? bin,YI Guang? xin,XIONG Bin,et al.Interventional treatment of early intrahepatic recurrence or metastasis of primary liver carcinoma after surgical resection: initial experience of 36 cases[J].journal interventional radiology,2013,(02):325.
[8]乔彬彬,虞希祥,王舒婷,等.TACE术中灌注氟尿嘧啶、奥沙利铂及吡柔比星治疗原发性肝癌的临床效果分析[J].介入放射学杂志,2015,(04):349.
 QIAO Bin bin,YU Xi xiang,WANG Shu ting,et al.TACE with infusion of fluorouracil, oxaliplatin and pirarubicin for the treatment of primary liver cancer: analysis of clinical effect[J].journal interventional radiology,2015,(02):349.
[9]黄 芳,龚环宇,熊正平.雷替曲塞联合奥沙利铂TACE治疗BCLC B/C期肝细胞癌的安全性及疗效[J].介入放射学杂志,2018,27(01):76.
 HUANG Fang,GONG Huanyu,XIONG Zhengping.The safety and efficacy of raltitrexed combined with oxaliplatin in TACE treatment for BCLC B/C hepatocellular carcinomas[J].journal interventional radiology,2018,27(02):76.
[10]刘 平,马晓晓,刘宝将,等.82例肝动脉灌注化疗致过敏反应患者的临床特征及护理对策[J].介入放射学杂志,2023,32(12):1242.
 LIU Ping,MA Xiaoxiao,LIU Baojiang,et al.Clinical features of patients with allergic reactions induced by hepatic arterial perfusion chemotherapy and its nursing strategy: preliminary results in 82 patients[J].journal interventional radiology,2023,32(02):1242.
[11]刘学芬,彭东,李刚,等.吉西他滨和奥沙利铂栓塞化疗联合三维适形放疗治疗晚期原发性肝癌疗效观察[J].介入放射学杂志,2013,(04):292.
 LIU Xue? fen,PENG Dong,LI Gang,et al.Transcatheter arterial chemoembolization with regimen GEMOX together with three?蛳 dimensional conformal radiotherapy for advanced primary hepatocellular carcinoma: a clinical observation[J].journal interventional radiology,2013,(02):292.

备注/Memo

备注/Memo:
(收稿日期:2012-10-15)
更新日期/Last Update: